Rare Disease Report

Ethan Perlstein

Over the course of the last decade, first as a graduate student at Harvard and then as an independent postdoctoral fellow at Princeton, Dr. Ethan Perlstein developed an approach to studying complex drugs in simple model organisms called evolutionary pharmacology. Last year Dr. Perlstein left academia in the face of “postdocalypse,” declared scientific independence, and decided to apply evolutionary pharmacology to orphan/rare diseases. His journey of professional reinvention includes forays into tweeting, blogging, and crowdfunding. It culminates in Perlstein Lab, PBC, a San Francisco-based biotech startup and public benefit corporation that is focused on precision orphan disease drug discovery.
February 09, 2015
Last month at the State of the Union, President Obama announced the $215M Precision Medicine Initiative (PMI).
December 26, 2014
Here are 3 more tips that become pertinent after you put your business and scientific plans into action:
November 28, 2014
So you want to start a rare disease company but don't know where to start.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.